LVLeonardo Vazquez

Leonardo Vazquez

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Leonardo Vazquez has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effects of cell growth and temperature on mitochondrial physiology of Drosophila melanogaster embryonic cell line

    by Rodiésley S. Rosa, Ana Paula M. Mendonça, Matheus P. Oliveira, Danielle B. Carvalho, Leonardo Vazquez, Marcus F. Oliveira

    The fruit fly Drosophila melanogaster is a valuable model for studying cellular and metabolic processes conserved with mammals. Using its embryonic Schneider S2 cell line, commonly used for heterologous protein expression, we investigated how culture duration and slight temperature changes affect mitochondrial physiology via high-resolution respirometry. We assessed five mitochondrial bioenergetic parameters and two coupling parameters at early and late growth phases, and at two temperatures (26°C and 28°C). We observed that a moderate temperature increase coupled with late growth phase synergistically enhanced basal, OXPHOS, and leak respiration, with only minor impacts on mitochondrial coupling efficiency. Notably, spare and maximal respiratory capacities increased disproportionately with either cell growth progression or moderate temperature rise, suggestive of enhanced mitochondrial biogenesis. These results demonstrate that small temperature increases and cell maturation activate mitochondrial bioenergetic capacity through mechanisms consistent with mitochondrial biogenesis and functional remodeling. Such adaptations improve cellular metabolic resilience while maintaining energy conversion efficiency. These findings deepen understanding of mitochondrial plasticity in response to environmental and developmental signals. They may inform strategies to optimize mitochondrial physiology in various biological contexts, including aging, metabolic diseases, and stress adaptation.

  • Open Access

    Evidence of Hyperglycemic Levels Improving the Binding Capacity between Human Serum Albumin and the Antihypertensive Drug Hydrochlorothiazide

    by Marilia Amável Gomes Soares, Franklin Souza-Silva, Carlos Roberto Alves, Leonardo Vazquez, Talita Stelling de Araujo, Carlos Serpa, Otávio Augusto Chaves

    Cardiovascular diseases (CVDs), especially arterial hypertension, stand as prominent contributors to global mortality. Regrettably, individuals with diabetes encounter a two-fold increase in the risk of mortality associated with CVDs. Hydrochlorothiazide (HCTZ) represents a primary intervention for hypertension, particularly in diabetic patients. Nevertheless, there has not yet been a comprehensive assessment of the biophysical characteristics regarding the impact of glucose levels on its binding affinity with human serum albumin (HSA). Thus, the present work reports the interactive profile of HSA/HCTZ in nonglycemic, normoglycemic (80 mg/dL), and hyperglycemic (320 mg/dL) conditions by time-resolved fluorescence, saturation transfer difference–nuclear magnetic resonance (STD-NMR), and surface plasmon resonance (SPR). There was a moderate ground state association of HSA/HCTZ with subdomain IIA that was affected in the presence of different glucose levels. The hyperglycemic condition decreased the binding affinity of HCTZ to subdomain IIA and increased the possibility of subdomain IB also being considered as a secondary binding site due to cooperativity and/or alterations in the protein’s structure. Overall, the glucose level under hyperglycemic conditions led to the cavities being more likely to receive more ligands, offering insights into the necessity of glucose control in the human bloodstream to not impact the residence time (pharmacokinetic profile) and pharmacotherapeutic potential of HCTZ.


  • Open Access

    Atazanavir Is a Competitive Inhibitor of SARS-CoV-2 Mpro, Impairing Variants Replication In Vitro and In Vivo

    by Otávio Augusto Chaves, Carolina Q. Sacramento, André C. Ferreira, Mayara Mattos, Natalia Fintelman-Rodrigues, Jairo R. Temerozo, Leonardo Vazquez, Douglas Pereira Pinto, Gabriel P. E. da Silveira, Laís Bastos da Fonseca, et al.

    Atazanavir (ATV) has already been considered as a potential repurposing drug to 2019 coronavirus disease (COVID-19); however, there are controversial reports on its mechanism of action and effectiveness as anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Through the pre-clinical chain of experiments: enzymatic, molecular docking, cell-based and in vivo assays, it is demonstrated here that both SARS-CoV-2 B.1 lineage and variant of concern gamma are susceptible to this antiretroviral. Enzymatic assays and molecular docking calculations showed that SARS-CoV-2 main protease (Mpro) was inhibited by ATV, with Morrison’s inhibitory constant (Ki) 1.5-fold higher than GC376 (a positive control) dependent of the catalytic water (H2Ocat) content. ATV was a competitive inhibitor, increasing the Mpro’s Michaelis–Menten (Km) more than sixfold. Cell-based assays indicated that different lineages of SARS-CoV-2 is susceptible to ATV. Using oral administration of ATV in mice to reach plasmatic exposure similar to humans, transgenic mice expression in human angiotensin converting enzyme 2 (K18-hACE2) were partially protected against lethal challenge with SARS-CoV-2 gamma. Moreover, less cell death and inflammation were observed in the lung from infected and treated mice. Our studies may contribute to a better comprehension of the Mpro/ATV interaction, which could pave the way to the development of specific inhibitors of this viral protease.


  • Open Access

    Molecular docking analysis on the interaction between bovine serum albumin and three commercial fluoroquinolones: Ciprofloxacin, enrofloxacin and pefloxacin

    by Otavio Augusto Chaves, Leonardo Vazquez

    Fluoroquinolones are a family of broad spectrum, systemic antibacterial agents that have been used as therapy for infections in the respiratory and alimentary tract in animals. The pharmacodynamic of this class is widely described, predominantly to the commercial drugs ciprofloxacin (CIP), enrofloxacin (ENR), and pefloxacin (PEF). Bovine serum albumin (BSA) is the main endogenous carrier in the bovine bloodstream, being responsible for the biodistribution of different classes of molecules and drugs, including fluoroquinolones. The molecular features and interaction between BSA and fluoroquinolones are not fully described, thus, the present work enlightens the intimacy of the interaction of BSA with CIP, ENR, PEF through structural modeling and molecular docking calculation approaches. The role of key amino acid residues was assessed, indicating that the main protein binding pocket is composed by Trp-212 residue playing an important stabilization for the three fluoroquinolones through both hydrogen bonding and van der Waals forces, where reside the individual structural differences observed among the three fluoroquinolones and BSA. There is a descriptive protagonism of carboxyl group on the ENR interaction which traps the molecule and avoids the deep communication in the protein binding pocket, as well as the ligands CIP and PEF showed an interface amino acid residue interaction profile higher than 70%.


  • BIOREMEDIATION OF CONTAMINATED AIR USING A BIOSCRUBBER

    by Fernando Jorge Santos Oliveira, Leonardo Vazquez, Francisca Pessoa de Franca